{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:19:02Z","timestamp":1794917942109,"version":"4.9.1"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Early initiation of antibiotics is essential for ameliorating infections in critically ill patients. The correct dosage of antibiotics is imperative to ensure their adequate exposure. Critically ill patients have altered pharmacokinetic parameters and are often infected by less susceptible microorganisms. Differences in drug disposition are not considered with standard doses of antibiotics. This can lead to suboptimal antibiotic exposure in critically ill patients. To overcome this problem of suboptimal dosing, therapeutic drug monitoring (TDM) is a strategy commonly used to support individualized dosing of antibiotics. It is routinely used for vancomycin and aminoglycosides in clinical practice. In recent years, it has become apparent that TDM may also be used in other antibiotics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This review summarizes the evidence for TDM of antibiotics in critically ill patients, focuses on clinical outcomes, and summarizes possibilities for optimized TDM in the future.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results and Conclusion:<\/jats:title>\n            <jats:p>After reviewing the literature, we can conclude that general TDM implementation is advised for glycopeptides and aminoglycosides, as evidence of the relationship between TDM and clinical outcome is present. For antibiotics, such as beta-lactams, fluoroquinolones, and linezolid, it seems rational to perform TDM in specific patient cases. TDM involving other antibiotics is supported by individual cases, specifically to decrease toxicity. When focusing on future possibilities to improve TDM of antibiotics in critically ill patients, implementation of model-informed precision dosing should be investigated because it can potentially streamline the TDM process. The logistics of TDM, such as turnaround time and available equipment, are challenging but may be overcome by rapid bioanalytical techniques or real-time monitoring of drug concentrations through biosensors in the future. Education, clinical information on targets, and clinical outcome studies are other important factors that facilitate TDM implementation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000942","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T07:00:12Z","timestamp":1636786812000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome"],"prefix":"10.1097","volume":"44","author":[{"given":"Birgit C. P.","family":"Koch","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk E.","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Haaglanden Medical Center, The Hague, the Netherlands;"},{"name":"Department of Medical Microbiology & Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G. M.","family":"Hunfeld","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands;"},{"name":"Department of Adult Intensive Care, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim M. J.","family":"Ewoldt","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands;"},{"name":"Department of Adult Intensive Care, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Endeman","sequence":"additional","affiliation":[{"name":"Department of Adult Intensive Care, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00134-015-3906-y","article-title":"The surviving sepsis campaign bundles and outcome: results from the international multicentre prevalence study on sepsis (the impress study)","volume":"41","author":"Rhodes","year":"2015","journal-title":"Intensive Care Med."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (expat)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"Dali: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2334-12-152","article-title":"Dali: defining antibiotic levels in intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic","volume":"12","author":"Roberts","year":"2012","journal-title":"BMC Infect Dis."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"e77169","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the dolphin trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ACO.0b013e328339ef0a","article-title":"Pharmacokinetics and pharmacodynamics in critically ill patients","volume":"23","author":"Varghese","year":"2010","journal-title":"Curr Opin Anaesthesiol."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/0310057X1103900602","article-title":"Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story","volume":"39","author":"Lipman","year":"2011","journal-title":"Anaesth Intensive Care."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/ACO.0000000000000810","article-title":"Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?","volume":"33","author":"Abdul-Aziz","year":"2020","journal-title":"Curr Opin Anaesthesiol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2018.11.018","article-title":"Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen","volume":"53","author":"Wilkes","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller","year":"2013","journal-title":"J Antimicrob Chemother."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cmi.2015.06.007","article-title":"Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective","volume":"21","author":"Muller","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"e01275","DOI":"10.1128\/AAC.01375-20","article-title":"Clinical pharmacokinetics of fosfomycin after continuous infusion compared with intermittent infusion: a randomized crossover study in healthy volunteers","volume":"65","author":"Al Jalali","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/jac\/dky195","article-title":"Mic-based dose adjustment: facts and fables-authors' response","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"de Montmollin","year":"2014","journal-title":"Intensive Care Med."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"Galvez","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004","journal-title":"Pediatrics."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","article-title":"An international survey on aminoglycoside practices in critically ill patients: the AMINO III study","volume":"11","author":"Roger","year":"2021","journal-title":"Ann Intensive Care."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1186\/cc12844","article-title":"Therapeutic drug monitoring of amikacin in septic patients","volume":"17","author":"Duszynska","year":"2013","journal-title":"Crit Care."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.01674-10","article-title":"Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding","volume":"55","author":"Butterfield","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s40064-015-1146-9","article-title":"Optimization of time to initial vancomycin target trough improves clinical outcomes","volume":"4","author":"Cardile","year":"2015","journal-title":"Springerplus."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/FTD.0000000000000750","article-title":"Therapeutic drug monitoring coupled with Bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","article-title":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","volume":"26","author":"Dalton","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/FTD.0000000000000295","article-title":"Switching from intermittent to continuous infusion of vancomycin in critically ill patients: toward a more robust exposure","volume":"38","author":"van Maarseveen","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/IDR.S146961","article-title":"Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe gram-positive infections","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5414\/CP202247","article-title":"Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections","volume":"53","author":"Wang","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s10096-019-03652-6","article-title":"Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy","volume":"38","author":"Kim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R44-20250603","first-page":"15","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"8","author":"Matsumoto","year":"2016","journal-title":"Clin Pharmacol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Martin","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00228-020-02873-5","article-title":"Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients","volume":"76","author":"Abdulla","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.1989.00390100083020","article-title":"Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication","volume":"149","author":"Peloquin","year":"1989","journal-title":"Arch Intern Med."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00228-009-0717-5","article-title":"Seizures associated with levofloxacin: case presentation and literature review","volume":"65","author":"Bellon","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/WNL.0000000000002633","article-title":"Association between oral fluoroquinolones and seizures: a self-controlled case series study","volume":"86","author":"Chui","year":"2016","journal-title":"Neurology."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorli","year":"2013","journal-title":"BMC Infect Dis."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ph13030042","article-title":"Is there a role for the therapeutic drug monitoring of colistin? An overview","volume":"13","author":"Avila","year":"2020","journal-title":"Pharmaceuticals (Basel)."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijantimicag.2013.06.009","article-title":"Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring","volume":"42","author":"Bode-Boger","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"e00483","DOI":"10.1128\/AAC.00483-18","article-title":"Personalizing polymyxin b dosing using an adaptive feedback control algorithm","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkx409","article-title":"Pharmacokinetics\/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models","volume":"73","author":"Landersdorfer","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","article-title":"Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution","volume":"53","author":"Galar","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/antibiotics10030263","article-title":"Impact on antibiotic resistance, therapeutic success, and control of side effects in therapeutic drug monitoring (TDM) of daptomycin: a scoping review","volume":"10","author":"Osorio","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3476(78)80028-6","article-title":"Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of pneumocystis carinii pneumonia","volume":"92","author":"Hughes","year":"1978","journal-title":"J Pediatr."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/FTD.0000000000000282","article-title":"Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study","volume":"38","author":"Ice","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1128\/AAC.35.9.1884","article-title":"Pharmacokinetics and adverse effects of 20-mg\/kg\/day trimethoprim and 100-mg\/kg\/day sulfamethoxazole in healthy adult subjects","volume":"35","author":"Stevens","year":"1991","journal-title":"Antimicrob Agents Chemother."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/17425255.2021.1879049","article-title":"A narrative review of predictors for beta-lactam antibiotic exposure during empirical treatment in critically ill patients","volume":"17","author":"Abdulla","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1128\/AAC.01586-06","article-title":"Concentration-effect relationship of ceftazidime explains why the time above the mic is 40 percent for a static effect in vivo","volume":"51","author":"Mouton","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","article-title":"Cefepime free minimum concentration to minimum inhibitory concentration (fcmin\/mic) ratio predicts clinical failure in patients with gram-negative bacterial pneumonia","volume":"45","author":"Aitken","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (auic) and time above the minimum inhibitory concentration (t>mic) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"383.e381","DOI":"10.1016\/j.cmi.2018.11.020","article-title":"Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study","volume":"25","author":"Bricheux","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"e14632","DOI":"10.1097\/MD.0000000000014632","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of infectious diseases: meta-analysis and systematic review","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"R78-20250603","first-page":"63","article-title":"A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: BLING III","volume":"21","author":"Lipman","year":"2019","journal-title":"Crit Care Resusc."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00134-014-3550-y","article-title":"Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration","volume":"41","author":"De Pascale","year":"2015","journal-title":"Intensive Care Med."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/bios9040132","article-title":"Optical biosensors for therapeutic drug monitoring","volume":"9","author":"Garzon","year":"2019","journal-title":"Biosensors (Basel)."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1038\/s41467-018-04802-8","article-title":"Continuous biomarker monitoring by particle mobility sensing with single molecule resolution","volume":"9","author":"Visser","year":"2018","journal-title":"Nat Commun."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/cc10262","article-title":"A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance","volume":"15","author":"Baptista","year":"2011","journal-title":"Crit Care."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:43Z","timestamp":1748971783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000942","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}